Published Online
on March 6, 2008

A more recent version of this article appeared on May 1, 2008

This Article Full Text (PDF) All Versions of this Article: 39/5/1482    most recent STROKEAHA.107.500199v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Google Scholar Articles by Healey, J. S. Articles by Connolly, S. J. PubMed PubMed Citation Articles by Healey, J. S. Articles by Connolly, S. J. Related Collections Arrhythmias, clinical electrophysiology, drugs Other hypertension Coumarins Other anticoagulants Platelet function inhibitors Embolic stroke Related Article

Submitted on August 1, 2007
Revised on September 22, 2007
Accepted on October 3, 2007

Risks and Benefits of Oral Anticoagulation Compared With Clopidogrel Plus Aspirin in Patients With Atrial Fibrillation According to Stroke Risk. The Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE-W)

Jeff S. Healey MD, MSc^*; Robert G. Hart MD; Janice Pogue MSc; Marc A. Pfeffer MD, PhD; Stefan H. Hohnloser MD; Raffaele De Caterina MD; Greg Flaker MD; Salim Yusuf MD, DPhil; and Stuart J. Connolly MD

From the Population Health Research Institute (J.S.H., J.P., S.Y., S.J.C.), McMaster University, Hamilton, Canada; the University of Texas at San Antonio (R.G.H.), San Antonio, Tex; Brigham and Women's Hospital (M.A.P.), Harvard University, Boston, Mass; J.W. Goethe University (S.H.H.), Frankfurt, Germany; G. D'Annunzio University (R.D.C.), Chieta, Italy; and the University of Missouri (G.F.), Columbia, Mo.

^* To whom correspondence should be addressed. E-mail: healeyj{at}hhsc.ca.

Background and Purpose—In ACTIVE-W, oral anticoagulation (OAC) was more efficacious than combined clopidogrel plus aspirin (C+A) in preventing vascular events in patients with atrial fibrillation. However, because OAC carries important bleeding complications, risk stratification schemes have been devised to identify patients for whom the absolute benefits of OAC exceed its risks.

Methods—Participants were risk-stratified with the widely-used CHADS₂ scheme. Treatment-specific rates of stroke and major bleeding were calculated for patients with a CHADS₂=1 and compared to those with a CHADS₂>1.

Results—Observed stroke rates for those with a CHADS₂=1 were 1.25% per year on C+A and 0.43% per year on OAC (RR=2.96, 95% CI: 1.26 to 6.98, P=0.01). Among patients with a CHADS₂>1, the stroke rates were 3.15% per year on C+A and 2.01% per year on OAC (RR=1.58, 95% CI: 1.11 to 2.24, P=0.01) (P for interaction between stroke risk category and efficacy of OAC=0.19). The risk of major bleeding during OAC was significantly lower among patients with CHADS₂=1 (1.36% per year) compared with CHADS₂>1 (2.75% per year) (RR=0.49, 95% CI 0.30 to 0.79, P=0.003).

Conclusions—In this clinical trial, patients with a CHADS₂=1 had a low risk of stroke, yet still derived a modest (<1% per year) but statistically significant absolute reduction in stroke with OAC and had low rates of major hemorrhage on OAC.

Key words: atrial fibrillation • stroke • risk stratification • anticoagulation

Related Article:

The Balance Between Stroke Prevention and Bleeding Risk in Atrial Fibrillation: A Delicate Balance Revisited

Gregory Y.H. Lip
Stroke 2008 39: 1406-1408. [Full Text] [PDF]

This article has been cited by other articles:

				Stroke Risk in Atrial Fibrillation Working Group Comparison of 12 Risk Stratification Schemes to Predict Stroke in Patients With Nonvalvular Atrial Fibrillation Stroke, June 1, 2008; 39(6): 1901 - 1910. [Abstract] [Full Text] [PDF]

				G. Y.H. Lip The Balance Between Stroke Prevention and Bleeding Risk in Atrial Fibrillation: A Delicate Balance Revisited Stroke, May 1, 2008; 39(5): 1406 - 1408. [Full Text] [PDF]